Your session is about to expire
← Back to Search
Jaktinib for Myelofibrosis
Study Summary
This trial is testing whether Jaktinib can shrink the size of the spleen and improve symptoms in people with myelofibrosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You may be allergic to jaktinib or its ingredients.You have participated in another clinical trial for a new drug or medical device within the past 3 months.You are expected to live for more than 24 weeks.
- Group 1: Jaktinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been enrolled in this clinical research project?
"That is correct. The clinicaltrials.gov registry indicates that this research endeavour, initially posted on July 1st 2022, has commenced the recruitment process. 26 participants are being sought from a single site for the trial."
Has Jaktinib Hydrochloride Tablet been granted clearance by the FDA?
"Due to the limited amount of data available on Jaktinib Hydrochloride Tablet's safety and efficacy, our team has assigned it a score of 1."
Are there any open spots for individuals to take part in the experiment?
"Affirmative. Clinicaltrials.gov confirms that this research project, which went live on July 1st 2022 is actively seeking volunteers. Only 26 participants are needed and the study will be conducted at a single site."
Share this study with friends
Copy Link
Messenger